124 related articles for article (PubMed ID: 7624666)
1. [Cancer following treatment of Hodgkin disease].
Lustman F; Nouwynck C
Rev Med Brux; 1995; 16(3):138-40. PubMed ID: 7624666
[TBL] [Abstract][Full Text] [Related]
2. [Low grade non-Hodgkin's lymphoma after combined therapy for Hodgkin's disease].
Raya Sánchez JM; González Brito G; Hernández Nieto L; Brito Barroso ML; Alvarez Argüelles H; Jorge Hernández JA; Martín Herrera A
Sangre (Barc); 1994 Dec; 39(6):461-4. PubMed ID: 7855699
[TBL] [Abstract][Full Text] [Related]
3. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
[TBL] [Abstract][Full Text] [Related]
4. Incidence of second solid cancer in patients after treatment of Hodgkin's disease.
Glanzmann C; Veraguth A; Lütolf UM
Strahlenther Onkol; 1994 Mar; 170(3):140-6. PubMed ID: 8160093
[TBL] [Abstract][Full Text] [Related]
5. [Non-Hodgkin's lymphoma in a patient after many years of remission of Hodgkin's disease].
Kaźmierczak M; Komarnicki M; Kroll R
Acta Haematol Pol; 1995; 26(3):311-3. PubMed ID: 8525778
[TBL] [Abstract][Full Text] [Related]
6. [The probability of the carcinogenic risk of using nitrosomethylurea for treating cancer patients].
Korman DB
Vopr Onkol; 2000; 46(3):274-7. PubMed ID: 10976271
[TBL] [Abstract][Full Text] [Related]
7. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
8. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
Sacchi S; Marcheselli L; Bari A; Marcheselli R; Pozzi S; Luminari S; Lombardo M; Buda G; Lazzaro A; Gobbi PG; Stelitano C; Morabito F; Quarta G; Brugiatelli M
Haematologica; 2008 Mar; 93(3):398-404. PubMed ID: 18268277
[TBL] [Abstract][Full Text] [Related]
9. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease.
Mauch PM; Kalish LA; Marcus KC; Shulman LN; Krill E; Tarbell NJ; Silver B; Weinstein H; Come S; Canellos GP; Coleman CN
Cancer J Sci Am; 1995; 1(1):33-42. PubMed ID: 9166452
[TBL] [Abstract][Full Text] [Related]
11. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study.
Salloum E; Doria R; Farber LR; Roberts KB; Cooper DL
Cancer J Sci Am; 1995; 1(4):267-73. PubMed ID: 9166487
[TBL] [Abstract][Full Text] [Related]
12. Late complications of Hodgkin's disease management.
Young RC; Bookman MA; Longo DL
J Natl Cancer Inst Monogr; 1990; (10):55-60. PubMed ID: 2189477
[TBL] [Abstract][Full Text] [Related]
13. Peripheral T-cell non-Hodgkin's lymphoma following treatment of nodular lymphocyte predominance Hodgkin's disease.
Rysenga E; Linden MD; Carey JL; Ross CW; Schnitzer B; Sawdyk M; Maeda K
Arch Pathol Lab Med; 1995 Jan; 119(1):88-91. PubMed ID: 7802562
[TBL] [Abstract][Full Text] [Related]
14. Acute leukemia after the treatment of Hodgkin's disease.
Henry-Amar M; Dietrich PY
Hematol Oncol Clin North Am; 1993 Apr; 7(2):369-87. PubMed ID: 8468271
[TBL] [Abstract][Full Text] [Related]
15. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
Tebbi CK; London WB; Friedman D; Villaluna D; De Alarcon PA; Constine LS; Mendenhall NP; Sposto R; Chauvenet A; Schwartz CL
J Clin Oncol; 2007 Feb; 25(5):493-500. PubMed ID: 17290056
[TBL] [Abstract][Full Text] [Related]
16. Increased risk of second cancers in managing Hodgkins disease: the 20-year Leiden experience.
Sont JK; van Stiphout WA; Noordijk EM; Molenaar J; Zwetsloot-Schonk JH; Willemze R; Vandenbroucke JP
Ann Hematol; 1992 Nov; 65(5):213-8. PubMed ID: 1457578
[TBL] [Abstract][Full Text] [Related]
17. Solid second cancers following Hodgkin's disease.
Tucker MA
Hematol Oncol Clin North Am; 1993 Apr; 7(2):389-400. PubMed ID: 8468272
[TBL] [Abstract][Full Text] [Related]
18. [Late treatment related complications of Hodgkin's disease].
Henry-Amar M; Gisselbrecht C
Rev Prat; 1998 May; 48(10):1092-7. PubMed ID: 9781154
[TBL] [Abstract][Full Text] [Related]
19. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
[TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
Vassilakopoulos TP; Angelopoulou MK; Siakantaris MP; Kontopidou FN; Dimopoulou MN; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Karkantaris C; Anargyrou K; Boutsis DE; Variamis E; Michalopoulos T; Boussiotis VA; Panayiotidis P; Papavassiliou C; Pangalis GA
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):765-81. PubMed ID: 15183480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
